OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study

BACKGROUND: FGFR mutations and translocations occur in approximately 10% of glioblastomas (GBMs). FGFR3-TACC3 fusion has been reported as predictive of response to FGFR tyrosine kinase inhibitor therapy both pre-clinically and clinically. Infigratinib (BGJ398) is a selective small-molecule pan-FGFR...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Lassman, A B, Sepúlveda-Sánchez, J M, Cloughesy, T, Gil-Gil, J M, Puduvalli, V K, Raizer, J, De Vos, F Y, Wen, P Y, Butowski, N, Clement, P, Groves, M D, Belda-Iniesta, C, Steward, K, Moran, S, Ye, Y, Roth, P
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Oral Presentations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795586/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.072
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky